ERNA

Ernexa Therapeutics Inc

2.09

Oct 16 • 3:59 PM ET -0.08 (-3.69%)

2.17

Aftermarket • 7:40 PM ET +0.08 (3.83%)

Healthcare Biotechnology USA Nano NASD

Peers: GDTC BLRX GTBP ICU INTS KRSA MBRX TOVX BIVI GNTA

| Held by: VXF

Scroll to Statements

Index	-
Market Cap	3.41M
Enterprise Value	-1.27M
Income	-12.27M
Sales	0.00M
Book/sh	2.73
Cash/sh	3.08
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	5
IPO	Aug 29, 1991

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	0.76
P/C	0.68
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	2.01
Current Ratio	2.01
Debt/Eq	0.11
LT Debt/Eq	0.06
Option/Short	No / Yes

EPS (ttm)	-18.92
EPS next Y	-1.86
EPS next Q	-3.84
EPS this Y	67.76%
EPS next Y	89.68%
EPS next 5Y	71.68%
EPS past 3/5Y	73.56% 69.90%
Sales past 3/5Y	- -
EPS Y/Y TTM	99.03%
Sales Y/Y TTM	-100.00%
EPS Q/Q	77.65%
Sales Q/Q	-
Earnings	Aug 17
EPS/Sales Surpr.	0.00% -

Insider Own	30.04%
Insider Trans	0.00%
Inst Own	2.21%
Inst Trans	-5.19%
ROA	-176.37%
ROE	-320.70%
ROIC	-362.42%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-26.96%
SMA50	-44.47%
SMA200	-76.30%
Trades

Shs Outstand	1.17M
Shs Float	1.14M
Short Float	1.73%
Short Ratio	0.29
Short Interest	0.02M
52W High	71.50 -97.08%
52W Low	2.01 3.84%
Volatility	8.62% 11.75%
ATR (14)	0.33
RSI (14)	24.20
Beta	2.72
Rel Volume	0.36
Avg Volume	67.84K
Volume	24,617

Perf Week	-12.92%
Perf Month	-44.41%
Perf Quarter	-61.51%
Perf Half Y	-59.77%
Perf YTD	-93.03%
Perf Year	-93.31%
Perf 3Y	-99.72%
Perf 5Y	-100.00%
Perf 10Y	-100.00%
Recom	1.00
Target Price	30.00
Prev Close	2.17
Price	2.09
Change %	-3.69%

Oct-12-26 04:05PM	Ernexa Therapeutics to Participate in Virtual Investor Closing Bell Series (GlobeNewswire) -7.92%
Oct-06-26 08:55AM	Ernexa Therapeutics' ERNA-101 Selected for Flash Talk Presentation at Nature Conferences' Next-Generation Cancer Therapeutics Meeting Co-Hosted by MD Anderson Cancer Center (GlobeNewswire) -17.22%
Oct-01-26 09:20AM	Ernexa Therapeutics CEO Corner Highlights Appointment of Dr. Robert J. Spiegel as Company Sharpens Oncology Focus and Advances ERNA-101 Toward the Clinic (GlobeNewswire) -7.50%
Sep-30-26 08:32AM	Ernexa Therapeutics Reports Compelling ERNA-101 Safety Results Across Three Critical IND-Enabling Studies, Advancing Toward Planned Q4 2026 IND (GlobeNewswire)
Sep-29-26 09:15AM	Ernexa Therapeutics Selected for Emerging Track at 2026 Cell & Gene Meeting on the Mesa, Highlighting ERNA-101 and Focused Oncology Strategy (GlobeNewswire) -8.93%
08:42AM	Loading…
Sep-17-26 08:42AM	Ernexa Therapeutics Appoints Accomplished Biopharmaceutical Executive Robert J. Spiegel, M.D., FACP, to Board of Directors (GlobeNewswire)
Sep-15-26 08:42AM	Ernexa Therapeutics Reports Positive Disease Modifying ERNA-201 Preclinical Data, Reinforcing iMSC Platform as Company Accelerates Oncology Strategy and ERNA-101 Toward First-in-Human Dosing (GlobeNewswire)
Sep-14-26 09:05AM	Ernexa Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference (GlobeNewswire)
Aug-27-26 09:01AM	Ernexa Therapeutics Participates in the Virtual Investor "Why Now" On-Demand Conference (GlobeNewswire)
Aug-10-26 09:01AM	Ernexa Therapeutics Strengthens Board with Veteran Biotech Executive David Polinsky as Company Approaches Clinical Stage (GlobeNewswire) +7.60%
Jul-24-26 09:20AM	Ernexa Therapeutics CEO Corner Emphasizes How ERNA-101 Could Help Unlock the Next Generation of Combination Cancer Therapies (GlobeNewswire)
Jul-15-26 09:43AM	Ernexa Therapeutics shares soar 30% after independent study validates cancer therapy (ERNA) (InvestorsHub) +11.06%
08:49AM	After Crinetics' $10 Billion Deal, Could Entera Bio Be the Next Category-Defining Oral Peptide Story? (FinanceWire)
07:50AM	Ernexa Therapeutics Receives Independent Validation of ERNA-101 with Complete Tumor Clearance and Durable Survival in Ovarian Cancer Models Ahead of Planned Clinical Entry (GlobeNewswire)
Jul-14-26 09:01AM	Ernexa Therapeutics CEO Corner Highlights Differentiated ERNA-101 Platform as Company Advances Toward Planned First-in-Human Phase 1 Study in 2026 (GlobeNewswire) +9.39%
09:15AM	Loading…
Jun-25-26 09:15AM	Ernexa Therapeutics Launches CEO Corner to Provide Deeper Insights into Company Progress, Scientific Strategy and Vision for Patients (GlobeNewswire) +17.46%
Jun-17-26 08:47AM	Ernexa Therapeutics Positioned to Become a Clinical-Stage Biotechnology Company as ERNA-101 On Track for Planned Q3 2026 IND Submission and First-in-Human Study (GlobeNewswire)
Jun-09-26 08:41AM	Ernexa Therapeutics Highlights Ovarian Cancer Unmet Need, Hope for Patients and Potential Accessibility Advantages of ERNA-101 in Virtual Investor KOL Connect Segment Featuring Dr. Ira Winer (GlobeNewswire) -7.98%
May-27-26 08:11AM	Ernexa Therapeutics Successfully Completes Key Manufacturing and IND Preparation Milestones for ERNA-101 Toward First-in-Human Clinical Development (GlobeNewswire)
May-20-26 08:31AM	Ernexa Therapeutics Releases Virtual Investor KOL Connect Segment Featuring Dr. Elena Ratner Highlighting Ovarian Cancer Landscape and ERNA-101 Opportunity (GlobeNewswire)
May-11-26 09:15AM	Ernexa Therapeutics Releases Virtual Investor KOL Connect Segment Highlighting Ovarian Cancer Landscape and Lead Candidate ERNA-101 (GlobeNewswire)
May-06-26 10:40AM	Ernexa Therapeutics (ERNA) Preclinical Data Shows 100% Survival and Complete Tumor Clearance in Ovarian Cancer Models (InvestorsHub) +51.38%
10:30AM	BC-Most Active Stocks (Associated Press)
08:33AM	Ernexa Therapeutics Unveils Breakthrough Preclinical Results: ERNA-101 Achieves 100% Survival and Complete Tumor Elimination in Ovarian Cancer Models (GlobeNewswire)
Apr-30-26 09:00AM	Ernexa Therapeutics Announces 1-for-25 Reverse Stock Split (GlobeNewswire) -21.24%
Mar-31-26 08:55AM	Ernexa Therapeutics Highlights Key Catalysts as Company Advances Toward First-in-Human Clinical Trials in 2026 (GlobeNewswire) +5.29%
Feb-20-26 09:05AM	Ernexa Therapeutics to Participate in Virtual Investor Closing Bell Series (GlobeNewswire) -17.25%
Feb-06-26 09:25AM	Ernexa Therapeutics Announces Pricing of $10.5 Million Public Offering (GlobeNewswire) -44.66%
Feb-03-26 08:45AM	Ernexa Therapeutics Participates in Virtual Investor "What This Means" Segment Highlighting Recent Successful Pre-IND Meeting with U.S. FDA (GlobeNewswire) -25.80%
Jan-27-26 08:45AM	Ernexa Therapeutics Selected as One of Only Ten Global Companies for Prestigious JETRO Japan Entry Acceleration Program (GlobeNewswire)
08:15AM	Loading…
Jan-06-26 08:15AM	Ernexa Therapeutics Announces Successful Pre-IND FDA Meeting and Continues Progress Toward First-in-Human Trial in Ovarian Cancer (GlobeNewswire)
Dec-08-25 08:30AM	Ernexa Therapeutics Presents New Preclinical Data at American Society of Hematology (ASH) Annual Meeting on Lead Cell Therapy Candidate for Treatment of Ovarian Cancer (GlobeNewswire)
Dec-03-25 08:30AM	Ernexa Therapeutics Announces Oral Presentation at the 67th American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
Dec-02-25 08:50AM	Ernexa Therapeutics Strengthens Scientific and Medical Advisory Board with Appointment of Leading Oncologist Dr. Ira S. Winer, M.D., Ph.D., FACOG (GlobeNewswire)
Nov-11-25 07:00AM	Ernexa Therapeutics to Present at Oxford Global's Cell 2025 (GlobeNewswire) -5.39%
Nov-10-25 08:35AM	Ernexa Therapeutics Reports Strong Quarterly Performance, Highlighting Operational Execution and Progress Toward First-in-Human Cell Therapy Trials (GlobeNewswire)
Nov-06-25 09:15AM	Ernexa Therapeutics Showcases Strategic Partnership with Cellipont Bioservices to Advance Toward First-in-Human Trials on Virtual Investor "What This Means" Platform (GlobeNewswire)
Oct-29-25 08:33AM	Cellipont Bioservices and Ernexa Therapeutics Enter Cell Therapy Manufacturing Partnership to Advance ERNA-101 Toward Clinical Trials in Ovarian Cancer (PR Newswire) +40.80%
Oct-01-25 08:30AM	Ernexa Therapeutics to Deliver Company Presentation at the Annual Cell & Gene Meeting on the Mesa (GlobeNewswire)
Sep-29-25 08:30AM	Ernexa Therapeutics President & CEO Sanjeev Luther to Present on Expert Panel at 5th Annual iPSC Drug Development Summit (GlobeNewswire)
Sep-17-25 08:30AM	Ernexa Therapeutics to Present New Data in Oral Presentation at AACR Special Conference in Cancer Research (GlobeNewswire) -5.22%
Sep-10-25 08:30AM	Ernexa Therapeutics Provides Update on Operational Excellence and Performance (GlobeNewswire)
Sep-03-25 09:30AM	Ernexa Therapeutics Announces Presentation At The H.C. Wainwright 27th Annual Global Investment Conference (GlobeNewswire)
Jul-09-25 08:30AM	Ernexa Therapeutics Regains Compliance with Nasdaq Listing Requirements (GlobeNewswire)
Jun-25-25 08:30AM	Ernexa Therapeutics Expands Advisory Board to Form Integrated Scientific and Medical Advisory Board as it Prepares for Clinical Development (GlobeNewswire) -5.05%
Jun-24-25 08:30AM	Ernexa Therapeutics Secures $6 Million in Second Closing Under Securities Purchase Agreement (GlobeNewswire) -17.50%
Jun-11-25 09:35AM	Ernexa Therapeutics announces 1-for-15 reverse stock split (TipRanks)
Jun-10-25 09:30AM	Ernexa Therapeutics Announces 1-for-15 Reverse Stock Split (GlobeNewswire) -17.99%
May-28-25 08:30AM	Ernexa Therapeutics Announces New Data to be Presented at ASCO Annual Meeting 2025 (GlobeNewswire)
May-14-25 08:30AM	Ernexa Therapeutics Establishes Texas Subsidiary to Support Continued Development of ERNA-101 and Future Clinical Operations (GlobeNewswire) +13.11%
May-08-25 08:30AM	Ernexa Therapeutics Announces Participation in the D. Boral Capital Inaugural Global Conference (Newsfile)
Apr-29-25 08:30AM	Ernexa Therapeutics Presented Promising Data on Innovative Cell Therapy Treatment at AACR Annual Meeting 2025 (GlobeNewswire)
Apr-22-25 08:30AM	Ernexa Therapeutics Announces New Data to be Presented at AACR Annual Meeting 2025 (GlobeNewswire)
Apr-03-25 08:55AM	Ernexa Therapeutics Closes New Funding Round (GlobeNewswire) -5.24%
Mar-25-25 08:30AM	Eterna Therapeutics Changes Name to Ernexa Therapeutics to Reflect New Strategic Focus on Ovarian Cancer and Autoimmune Disease (GlobeNewswire) -5.77%
Feb-26-25 08:30AM	Eterna Therapeutics Hosts Successful Inaugural Meeting with Newly Formed Scientific Advisory Board to Advance Cell Therapy Pipeline (GlobeNewswire)
Jan-29-25 08:46AM	Eterna appoints Zeldis, Sather to scientific advisory board (TipRanks)
Jan-28-25 08:30AM	Eterna Therapeutics Announces Expansion of Scientific Advisory Board (GlobeNewswire)
Jan-14-25 08:30AM	Eterna Therapeutics Announces Positive Preclinical Study Results on Lead Product ERNA-101 in Ovarian Cancer (GlobeNewswire) +48.22%
Jan-09-25 07:30AM	Eterna Therapeutics Announces Appointment of Dr. Elena Ratner to Board of Directors (GlobeNewswire)
Dec-03-24 08:30AM	Eterna Therapeutics Launches Research to Evaluate its Lead Induced Mesenchymal Stem Cell Therapy Candidate's (ERNA-101) Ability to Induce and Modulate Antitumor Immunity in Ovarian Cancer and Breast Cancer Models (GlobeNewswire) -9.95%
Nov-25-24 08:30AM	Eterna Therapeutics Announces Up to $1 Million Stock Repurchase Program (GlobeNewswire)
Nov-14-24 08:30AM	Eterna Therapeutics Regains Compliance with NASDAQ for Continued Listing (GlobeNewswire)
Oct-30-24 08:30AM	Eterna Therapeutics Completes Strategic Financial Restructuring with the Aim to Accelerate its Developmental Activities and Long-Term Success (GlobeNewswire)
Oct-18-24 08:06AM	Eterna, Factor announce license, collaboration agreement (TipRanks)
Oct-17-24 08:00AM	Eterna Therapeutics and Factor Bioscience Announce Exclusive License and Collaboration Agreement to Accelerate Cell Therapy Development for Oncology, Autoimmune, and Rare Diseases (GlobeNewswire)
May-14-24 10:53PM	ERNA Stock Earnings: Eterna Therapeutics Reported Results for Q1 2024 (InvestorPlace) +9.81% -9.79%
May-10-24 08:00AM	Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on Development of Beta 2 Microglobulin-Knockout (B2M-KO) iMSC Line with Enhanced Immunosuppressive Activity and Stealthing Features that May Further Augment the Therapeutic Potential of MSCs in Inflammatory Diseases (GlobeNewswire) -6.48%
May-08-24 09:31AM	Eterna Therapeutics Announces Appointment of Mahendra Rao, PhD, to its Scientific Advisory Board (GlobeNewswire) +12.12%
May-07-24 08:00AM	Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on the Development of a mRNA-Engineered iPSC Line which Mimics Native B2M Expression, via Targeted Insertion of HLA-E at the B2M Locus (GlobeNewswire) +12.50%
08:00AM	Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on Development of Beta 2 Microglobulin-Knockout (B2M-KO) iMSC Line with Enhanced Immunosuppressive Activity and Stealthing Features that May Further Augment the Therapeutic Potential of MSCs in Inflammatory Diseases (GlobeNewswire)
Mar-15-24 08:53AM	ERNA Stock Earnings: Eterna Therapeutics Reported Results for Q4 2023 (InvestorPlace)
Feb-20-24 08:30AM	Eterna Therapeutics Announces the Appointment of Peter Cicala, JD, to its Board of Directors (GlobeNewswire)
Jan-03-24 04:15PM	Eterna Therapeutics Grants New President and CEO Sanjeev Luther Inducement Award Under Nasdaq Listing Rule 5635 (c)(4) (GlobeNewswire)
Dec-21-23 11:18AM	Eterna Therapeutics Appoints Sanjeev Luther as President and CEO (Exec Edge)
Dec-20-23 04:15PM	Eterna Therapeutics Names Sanjeev Luther as President and Chief Executive Officer (GlobeNewswire) +9.87%
Dec-14-23 06:56PM	Eterna Therapeutics Announces $9.2 Million Convertible Debt and Warrant Financing (GlobeNewswire) +29.29% -16.57%
Nov-02-23 11:48AM	Eterna Therapeutics Appoints Dr. James Bristol to Board of Directors (Exec Edge) +8.13%
Nov-01-23 08:30AM	Eterna Therapeutics Appoints James Bristol, Ph.D., Pharmaceutical Research and Drug Discovery Veteran, to Board of Directors (GlobeNewswire) -12.76%
Sep-06-23 01:01PM	Eterna Therapeutics Teams with Lineage Cell on Transplant Therapies (Exec Edge)
09:40AM	EXCLUSIVE: Cell Therapy Player Lineage Cell Therapeutics Starts Development Activities Under Licensing Pact With Eterna Therapeutics (Benzinga)
08:00AM	Eterna Therapeutics Announces Initiation of Development Activities for Hypoimmune Pluripotent Cell Line for Neurology Indications Under Partnership With Lineage Cell Therapeutics (GlobeNewswire)
Sep-05-23 11:24AM	Eterna Therapeutics Appoints Dorothy Clarke to Board of Directors (Exec Edge)
08:30AM	Eterna Therapeutics Appoints Biopharma Industry Veteran Dorothy Clarke to Board of Directors (GlobeNewswire)
Jul-18-23 02:24PM	Eterna Therapeutics Announces $8.7M Private Placement Transaction (Exec Edge) +8.89%
08:00AM	Eterna Therapeutics Announces Completion of $8.7 Million of Convertible Debt Financing (GlobeNewswire)
Jul-11-23 11:21AM	Eterna Therapeutics Appoints Industry Veterans Binder, Wagner to Board of Directors (Exec Edge) +6.52%
08:30AM	Eterna Therapeutics Appoints Biotech Industry Veterans Brant Binder and Richard Wagner, Ph.D. to Board of Directors (GlobeNewswire)
May-24-23 11:18AM	Eterna Therapeutics Appoints Megan Yung as CSO, General Counsel (Exec Edge) -5.41%
08:30AM	Eterna Therapeutics Appoints Megan Yung as Chief Strategy Officer, General Counsel (GlobeNewswire)
May-17-23 08:30AM	Eterna Therapeutics and Factor Bioscience Announce New Data on Multi-Cell-Type Therapeutic Approach at American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting (GlobeNewswire) -5.73%
May-04-23 08:30AM	Eterna Therapeutics to Deliver Eight Presentations at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting (GlobeNewswire)
May-03-23 01:40PM	Eterna Therapeutics Buys Allogeneic Immuno-Oncology Platform from Exacis (Exec Edge)
May-02-23 07:30AM	Eterna Therapeutics Acquires Allogeneic Immuno-Oncology Platform from Exacis Biotherapeutics (GlobeNewswire)
Apr-11-23 08:00AM	Eterna Therapeutics and Lincoln Park Capital Enter into a Common Stock Purchase Agreement for Up To $10 Million (GlobeNewswire)
Mar-28-23 08:30AM	Jeff Karp, Ph.D., Joins Eternas Scientific Advisory Board (GlobeNewswire)
Mar-20-23 04:10PM	Eterna Therapeutics Reports Financial Results for Fourth Quarter and Full Year 2022 and Recent Business Highlights (GlobeNewswire) -7.74%
Mar-16-23 07:04AM	Insiders might want to re-evaluate their US$2.7m stock purchase as Eterna Therapeutics Inc. (NASDAQ:ERNA) drops to US$16m (Simply Wall St.) +10.00%
Feb-22-23 09:46AM	EXCLUSIVE: Lineage Cell Inks Exclusive Agreement For Novel Cell-Based Therapies With Potential In Neurology (Benzinga)
08:00AM	Eterna Therapeutics Enters Into Option and License Agreement with Lineage Cell Therapeutics to Develop Hypoimmune Pluripotent Cell Lines for Multiple Neurology Indications (GlobeNewswire)

Ernexa Therapeutics, Inc. engages in the research and development of cellular therapies. It is involved in the development of mRNA cell engineering technologies to repair cellular dysfunction and treat a range of therapeutic indications. Its pipeline includes ERNA-101 (Ovarian Cancer) and ERNA-201 (Rheumatoid Arthritis). The company was founded in 1984 and is headquartered in Cambridge, MA.

CEOMr. Sanjeev Luther

CITPMr. Mark J. Keeley CPA

Head of CMC & OperationsMs. Deborah Vee Wild

Chief Scientific OfficerDr. Robert Hamilton Pierce M.D.

General CounselMs. Dorothy J. Clarke

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Cherington Charles	10% Owner	Feb 10 '26	Buy	0.50	4,000,000	2,000,000	6,779,440	Feb 17 09:14 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ERNA

Ernexa Therapeutics Inc

Upgrade your Finviz experience